Mapp Biopharmaceutical, Inc.
Mapp Biopharmaceutical, Inc. develops novel pharmaceuticals for the prevention and treatment of infectious diseases, focusing on unmet needs in global health and biodefense. They are involved in developing antibody-based therapies and vaccines for diseases such as Ebola, Marburg, Nipah virus, and others, with a mission to address critical global health threats and biodefense challenges.
Industries
Nr. of Employees
small (1-50)
Mapp Biopharmaceutical, Inc.
San Diego, California, United States, North America
Products
Combination monoclonal antibody therapeutic for Sudan ebolavirus (investigational)
A two-antibody combination developed as a therapeutic candidate for treatment of disease caused by Sudan ebolavirus; advanced to Phase 1 clinical trial planning with public-sector funding support.
Pan-Marburg monoclonal antibody therapeutic (investigational)
A single human monoclonal antibody developed as a pan-Marburg virus therapeutic with demonstrated in vitro neutralization and in vivo protection in preclinical studies and advanced toward Phase 1 with government contract support.
Plant-produced multi-antibody filovirus therapeutic (experimental)
A multi-antibody cocktail produced in plant-based expression systems developed as an experimental therapeutic for Ebola and related filoviruses; progressed through preclinical testing and regulatory interactions.
Combination monoclonal antibody therapeutic for Sudan ebolavirus (investigational)
A two-antibody combination developed as a therapeutic candidate for treatment of disease caused by Sudan ebolavirus; advanced to Phase 1 clinical trial planning with public-sector funding support.
Pan-Marburg monoclonal antibody therapeutic (investigational)
A single human monoclonal antibody developed as a pan-Marburg virus therapeutic with demonstrated in vitro neutralization and in vivo protection in preclinical studies and advanced toward Phase 1 with government contract support.
Plant-produced multi-antibody filovirus therapeutic (experimental)
A multi-antibody cocktail produced in plant-based expression systems developed as an experimental therapeutic for Ebola and related filoviruses; progressed through preclinical testing and regulatory interactions.
Services
Consulting in pharmaceutical R&D and laboratory testing
Advisory and technical services in biotechnology research and development, laboratory testing, and commercialization strategy for antibody therapeutics.
Expanded access requests for investigational therapeutics
Operational handling of physician-submitted requests for individual-patient access to investigational antibody products, including triage and acknowledgement processes.
Consulting in pharmaceutical R&D and laboratory testing
Advisory and technical services in biotechnology research and development, laboratory testing, and commercialization strategy for antibody therapeutics.
Expanded access requests for investigational therapeutics
Operational handling of physician-submitted requests for individual-patient access to investigational antibody products, including triage and acknowledgement processes.
Expertise Areas
- Monoclonal antibody therapeutics
- Plant-based biomanufacturing
- Preclinical infectious disease models
- Antibody engineering and glycoengineering
Key Technologies
- Plant-based transient expression (Nicotiana)
- Monoclonal antibody engineering
- Fc glycoengineering (afucosylation, fucose-free variants)
- De novo MS/MS antibody sequencing